Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals (NYSE American: NBY) is promoting its Avenova and DERMAdoctor products during the Amazon Prime Early Access Sale on October 11-12, 2022. This event offers discounted prices for customers, enhancing sales opportunities for the Avenova brand, which achieved record one-day sales during the previous Prime Days. Avenova products are well-rated, receiving an average of 4.5 stars from over 12,000 reviews. DERMAdoctor, led by a board-certified dermatologist, includes various clinically proven skincare offerings. The company aims to attract new customers while providing significant discounts for loyal buyers.
NovaBay Pharmaceuticals (NBY) announced on October 3, 2022, that it received a notice from NYSE American regarding its common stock's low price, necessitating a reverse stock split or price improvement by April 3, 2023, to maintain its listing. The company plans to hold a Special Meeting on November 10, 2022, to seek shareholder approval for a reverse stock split ranging from 1-for-10 to 1-for-35. The initiative aims to raise the stock price and improve marketability, enhancing appeal to investors while supporting growth strategies through recent financing.
NovaBay Pharmaceuticals (NYSE American: NBY) will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29 at 9:00 a.m. Eastern time. The event takes place at the Sofitel Hotel in New York. A webcast of the presentation will be available on the company's website. NovaBay specializes in developing and commercializing scientifically formulated eyecare and skincare products, including the Avenova lid and lash spray, the most prescribed in its category, and the DERMAdoctor skincare line. For more information, visit novabay.com.
NovaBay Pharmaceuticals (NBY) has transitioned from a single-product company to a three-brand organization in eyecare, skincare, and wound care. CEO Justin Hall highlighted strong sales growth for Avenova with over 600 units sold daily, an 18% year-over-year increase. The company plans a reverse stock split to enhance stock market performance and has engaged with new partners to expand into European and Chinese markets. Anticipated revenue boosts from seasonal orders and new product launches were noted, driving confidence in future growth.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced its participation in the Virtual Life Sciences Investor Forum on September 15, 2022, at 1:00 p.m. Eastern Time. The company will also hold investor one-on-one meetings on September 16 and September 19-20. NovaBay specializes in developing scientifically formulated eyecare and skincare products, including the leading antimicrobial spray, Avenova, and the premium skincare brand DERMAdoctor. Investors can register for the conference here.
NovaBay Pharmaceuticals will feature its Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on the QVC show 'Girls’ Night In' on
NovaBay Pharmaceuticals (NBY) announced a private placement of 3,250 shares of its Series C Non-Voting Convertible Preferred Stock at $1,000 each, alongside Series A-1 and A-2 warrants. The expected gross proceeds are approximately $3.25 million. The company plans to use these funds for working capital and general corporate purposes. The placement is subject to stockholder approval and involves a reverse stock split to accommodate the conversion of the preferred stock and exercise of the warrants. Additionally, NovaBay is engaging in warrant reprice transactions for existing shareholders.
NovaBay Pharmaceuticals, Inc. (NBY) reported a 43% increase in product revenue for Q2 2022, reaching $3.0 million compared to $2.1 million last year. The growth is attributed to successful digital marketing initiatives and the acquisition of DERMAdoctor products. Year-to-date revenue also surged 44% to $5.7 million. However, gross margins dipped to 51% from 71% due to higher sales of DERMAdoctor products. The company incurred a net loss of $2.2 million, consistent with the previous year. As of June 30, 2022, cash reserves were $3.9 million.
NovaBay Pharmaceuticals (NBY) will announce its financial results for the six months ended June 30, 2022, on August 11, 2022, following market close. An investment community conference call is scheduled for the same day at 4:30 p.m. Eastern time, with options for pre-registration and dial-in access. A live webcast will also be available, along with a replay accessible until September 1, 2022. NovaBay focuses on problem-solving health solutions through its brands Avenova and DERMAdoctor, which address eye irritations and skincare issues, respectively.
NovaBay Pharmaceuticals (NYSE American: NBY) has launched a new marketing campaign targeting women who use eyelash extensions, aiming to expand the Avenova brand into this growing market. Avenova is recognized as a premier antimicrobial spray, and the campaign integrates pharmaceutical expertise with beauty, addressing the need for lash care. The global lash extension market is expected to grow 7.6% annually to $2.4 billion by 2031, with Avenova providing a solution to issues like irritation and infection while prolonging the life of extensions.
